zika
viru
emerg
pathogen
gain
signific
import
epidem
south
central
america
unusu
alarm
complic
infect
recogn
although
initi
consid
selflimit
benign
infect
panopli
neurolog
complic
recogn
includ
syndrom
inutero
fetal
infect
caus
microcephali
blind
congenit
neurolog
complic
numer
zika
viru
vaccin
develop
nine
differ
vaccin
repres
five
differ
platform
enter
clinic
trial
one
progress
phase
ii
review
current
landscap
challeng
confront
zika
viru
vaccin
develop
zika
viru
discov
uganda
shown
endem
subsaharan
africa
tropic
area
southeastern
asia
studi
second
half
centuri
isol
outbreak
occur
yap
island
french
polynesia
start
zika
viru
infect
achiev
epidem
statu
spread
rapidli
south
america
central
america
caribbean
island
soon
recogn
zika
viru
infect
occur
pregnanc
caus
microcephali
congenit
disord
develop
fetu
latter
primari
reason
world
health
organ
label
zika
intern
threat
earli
begin
late
numer
academ
lab
pharmaceut
compani
initi
work
develop
vaccin
zika
howev
time
first
vaccin
enter
clinic
trial
zika
epidem
start
wane
creat
signific
challeng
vaccin
assess
engend
discuss
regulatori
pathway
licensur
paper
provid
brief
updat
current
progress
zika
viru
vaccin
develop
explor
challeng
vaccin
assess
eventu
licensur
zika
viru
infect
present
symptom
complex
consist
diffus
maculopapular
rash
fever
asthenia
myalgia
arthralgia
headach
retroorbit
pain
frequenc
degre
symptomatolog
howev
vari
studi
retrospect
studi
immedi
follow
outbreak
yap
island
found
survey
particip
report
symptom
consist
zika
viru
infect
figur
cite
suggest
zika
viru
infect
asymptomat
mani
individu
howev
individu
provid
blood
sampl
repres
household
symptomat
second
retrospect
studi
larger
outbreak
french
polynesia
similarli
appear
low
rate
symptomatolog
base
sampl
blood
donor
howev
subsequ
seropreval
studi
found
evid
prior
infect
symptom
consist
zika
viru
infect
recent
metaanalysi
studi
note
case
report
asymptomat
although
author
note
assess
preval
symptom
goal
mani
studi
adult
common
report
complic
zika
viru
infect
ill
preval
case
per
case
infect
french
polynesian
epidem
interest
recent
metaanalysi
question
causal
associ
less
common
report
neurolog
complic
adult
includ
meningoenceph
adem
ill
contrast
infect
pregnanc
associ
fetal
microcephali
number
congenit
ill
includ
visual
deficit
hear
disord
neural
calcif
learn
disabl
arthrogryposi
may
affect
mani
children
born
mother
infect
pregnanc
addit
zika
directli
invad
placenta
associ
prolong
matern
viremia
zika
viru
also
transmit
sexual
contact
first
report
research
return
seneg
numer
subsequ
case
report
publish
among
travel
part
epidem
affect
america
frequenc
sexual
transmiss
endem
region
unknown
could
differenti
mosquitoborn
transmiss
zika
viru
carriag
male
urogenit
tract
common
day
post
infect
may
persist
month
mice
zika
viru
infect
caus
testicular
atrophi
significantli
decreas
spermat
function
fertil
rate
one
studi
zika
viru
dna
vaccin
advers
effect
male
reproduct
system
prevent
vaccin
question
whether
zika
viru
advers
affect
human
reproduct
potenti
whether
effect
would
agerel
unknown
femal
may
also
excret
zika
viru
rna
extend
time
prospect
studi
five
women
show
zika
rna
detect
vagin
fluid
long
month
month
three
five
murin
studi
show
zika
viru
caus
infect
ovari
nonimmunosuppress
mice
induc
tcell
inflammatori
reaction
without
affect
reproduct
potenti
contrast
human
studi
femal
macaqu
rapidli
clear
viru
genit
tract
thu
zika
viru
infect
mildli
symptomat
selflimit
vast
major
individu
infrequ
neurolog
complic
adult
vaccin
gener
popul
may
warrant
howev
vaccin
femal
enter
reproduct
age
male
partner
prudent
discuss
previous
vaccin
pregnanc
nonid
due
time
gener
protect
immun
unknown
vaccin
safeti
one
unknown
aspect
whether
vaccin
male
age
may
benefici
protect
testicular
complic
call
gener
vaccin
program
howev
put
hold
due
decreas
incid
zika
infect
rate
discuss
next
section
late
global
concern
spread
epidem
increas
howev
experi
two
prior
epidem
predict
subsequ
epidemiolog
america
zika
viru
outbreak
yap
island
french
polynesia
character
rapid
onset
rapid
resolut
span
month
zika
epidem
america
character
longer
time
reach
peak
incid
take
approxim
one
year
brazil
presum
relat
larger
vari
geographi
attack
rate
decreas
greater
next
year
data
publish
pan
american
health
organ
paho
found
similar
pattern
south
central
america
http
wwwpahoorg
almost
complet
disappear
zika
creat
signific
barrier
ongo
vaccin
studi
attack
rate
fallen
need
meet
reason
sampl
size
remov
design
zika
viru
global
concern
case
rate
fallen
march
nation
institut
allergi
infecti
diseas
niaid
conven
meet
academ
repres
industri
regul
discuss
approach
zika
viru
vaccin
develop
era
wane
incid
although
zika
viru
remain
endem
asia
africa
central
south
america
current
transmiss
rate
coupl
high
background
herd
immun
would
requir
extrem
larg
logist
difficult
studi
popul
immun
wane
futur
outbreak
like
abil
conduct
meaning
futur
clinic
trial
may
depend
upon
preexist
site
regulatori
approv
establish
vaccin
network
enabl
rapid
respons
new
report
suggest
increas
diseas
activ
vaccin
develop
zika
viru
began
earnest
late
follow
report
microcephali
fetus
infant
brazil
note
first
demonstr
immunoprotect
part
studi
defin
ultrastructur
characterist
zika
viru
found
intramuscular
vaccin
mice
infecti
viral
filtrat
protect
cerebr
infect
poland
et
al
provid
comprehens
list
almost
zika
viru
vaccin
develop
diamond
et
al
discuss
potenti
immunoreact
epitop
zika
envelop
provid
inform
vaccin
progress
clinic
trial
larg
number
deliveri
platform
includ
live
attenu
inactiv
wholevirus
viralvector
vaccin
util
adenoassoci
viru
vesicular
stomat
viru
measl
viru
dengu
yellow
fever
chimer
vaccin
dna
mrna
vaccin
peptid
protein
subunit
vaccin
assess
anim
model
util
nonhuman
primat
andor
lethal
challeng
experi
involv
immunosuppress
mice
six
vaccin
advanc
phase
studi
sinc
time
two
addit
vaccin
enter
clinic
trial
tabl
total
three
dna
vaccin
enter
human
test
includ
one
advanc
phase
ii
tabl
dna
vaccin
encod
zika
viru
prme
gene
design
consensu
base
avail
zika
viru
sequenc
decemb
first
enter
clinic
trial
preclin
studi
vaccin
mice
nonhuman
primat
shown
develop
b
tcell
immun
respons
zika
viru
envelop
protect
develop
neurolog
diseas
death
immunosuppress
interferon
receptor
defici
ifnar
mice
moreov
histolog
section
brain
tissu
show
vaccin
mice
without
inflammatori
infiltr
evid
nonimmun
mice
subsequ
studi
show
vaccin
protect
testicular
damag
testicular
atrophi
spermatozo
damag
infertil
mice
phase
studi
evalu
administ
via
intraderm
inject
id
follow
electropor
ep
dose
either
mg
per
vaccin
follow
immedi
electropor
baselin
week
week
seriou
advers
event
sae
report
part
studi
frequent
advers
event
relat
discomfort
pain
swell
inject
site
seroconvers
observ
individu
two
vaccin
three
vaccin
neutral
antibodi
detect
particip
verocel
monkey
kidney
cell
assay
howev
particip
demonstr
abil
neutral
infect
neuroblastoma
cell
vaccin
respons
maintain
year
followup
differ
respons
base
dose
level
notabl
passiv
transfer
immun
serum
vaccin
particip
abl
protect
ifnar
mice
lethal
infect
independ
presenc
vero
cell
neutral
antibodi
evalu
part
second
doubleblind
placebocontrol
clinic
trial
perform
puerto
rico
analysi
latter
studi
progress
two
addit
dna
vaccin
base
french
polynesian
strain
develop
chimera
includ
jev
prm
signal
sequenc
follow
zika
envelop
e
gene
similar
construct
termin
amino
acid
e
repres
stem
transmembran
region
exchang
analog
jev
sequenc
vaccin
immunogen
mice
nhp
protect
nhp
viremia
dose
either
mg
given
twice
vaccin
candid
advanc
clinic
trial
mg
administ
intramuscularli
week
vaccin
administ
needl
syring
administ
either
singl
dose
split
dose
needl
syring
split
dose
given
pharmajet
needlefre
devic
seroconvers
group
administ
vaccin
needlefre
devic
less
vaccin
administ
splitdos
needl
syring
lowest
vaccin
given
singl
inject
needl
syring
vaccin
advanc
phase
ii
studi
america
util
clinic
site
clinic
site
select
guid
epidemiolog
model
longterm
followup
report
three
inactiv
vaccin
enter
clinic
studi
clinic
data
zpiv
vaccin
publish
zpiv
whole
inactiv
viru
vaccin
puerto
rican
strain
studi
mice
show
singl
vaccin
given
intramuscularli
alum
gener
antibodi
titer
approxim
fulli
protect
balbc
immunocompet
mice
viremia
wherea
unvaccin
mice
unprotect
subcutan
vaccin
mice
partial
protect
zika
brazil
strain
subsequ
studi
nonhuman
primat
vaccin
twice
fourweek
interv
alum
gener
bind
microneutr
antibodi
titer
respect
complet
protect
viremia
viruria
follow
challeng
either
brazilian
puerto
rican
strain
zika
viru
zpiv
safeti
immunogen
test
three
clinic
trial
assess
zika
vaccin
respons
rel
dose
level
vaccin
schedul
follow
vaccin
either
yellow
fever
yfvax
japanes
enceph
viru
jev
ixaro
vaccin
assess
respons
flavivirusexpos
popul
vaccineassoci
sae
report
common
advers
event
pain
tender
inject
site
neurolog
event
report
seroconvers
use
cutoff
peak
geometr
mean
titer
use
titer
respons
rate
singl
immun
use
cutoff
respect
vaccin
respons
observ
day
passiv
transfer
purifi
igg
deriv
zika
immun
particip
group
balbc
mice
per
particip
provid
steril
immun
viremia
mice
overal
viremia
observ
one
mice
per
group
inocul
sera
five
individu
clinic
trial
data
vaccin
yet
report
date
monograph
howev
preclin
data
report
three
candid
vaccin
mrna
vaccin
incorpor
prme
gene
micronesian
strain
zika
viru
creat
incorpor
without
fourpoint
mutat
fusionloop
segment
dii
region
envelop
gene
abolish
bind
antibodi
direct
fusionloop
region
reduc
potenti
risk
antibodydepend
enhanc
infect
immun
mice
unmodifi
lipid
nanoparticleencapsul
vaccin
mrna
immunogen
protect
lethal
infect
immun
immunocompet
mice
follow
treatment
block
antibodi
show
protect
viremia
approxim
anim
pizv
inactiv
vaccin
deriv
puerto
rican
strain
select
without
passagerel
mutat
protect
lethal
zika
viru
challeng
mice
administ
alum
adjuv
measlesvector
vaccin
encod
zika
viru
prme
shown
lessen
viremia
pregnant
ifnar
mice
prevent
clinic
diseas
mous
pup
preclin
data
inactiv
viral
vaccin
live
viru
vaccin
yet
report
number
anim
model
assess
vaccin
develop
review
elsewher
immunocompet
mice
develop
transient
viremia
follow
infect
may
repres
model
test
steril
immun
interferon
receptor
knockout
mice
ifnar
develop
lethal
infect
follow
zika
viru
infect
use
stringent
measur
protect
nonhuman
primat
develop
selflimit
mild
ill
associ
viremia
transmit
viru
utero
primat
fetu
logist
difficulti
pursu
standard
vaccin
evalu
creat
signific
interest
possibl
control
human
infect
model
chim
conduct
plan
human
challeng
trial
rais
uniqu
medic
ethic
consider
zika
viru
trial
one
must
balanc
rel
benign
selflimit
infect
experienc
vast
major
risk
less
benign
complic
transmiss
risk
review
publish
studi
provid
estim
zika
viru
infect
rel
asymptomat
selflimit
major
individu
howev
methodolog
studi
vari
wide
adult
two
set
complic
warrant
consider
propos
chim
studi
review
guillainbarrelik
syndrom
occur
approxim
zika
viru
infect
wherea
neurolog
complic
meningoenceph
myeliti
acut
dissemin
encephalomyel
rare
second
perhap
import
risk
transmiss
sexual
partner
potenti
infect
pregnanc
zika
viru
commonli
persist
male
urogenit
tract
month
may
persist
individu
month
consid
limit
studi
nonpregn
femal
zika
viru
colon
femal
genit
tract
may
tempor
limit
fact
zika
viru
known
caus
testicular
atrophi
mice
rais
yet
anoth
yet
theoret
concern
human
question
well
theoret
potenti
vectorborn
transmiss
debat
detail
late
conclus
benefit
human
challeng
infect
outweigh
risk
howev
analysi
perform
initi
epidem
wave
america
end
group
publish
followup
despit
recognit
conduct
placebocontrol
vaccin
trial
becom
significantli
difficult
due
declin
case
rate
group
conclus
essenti
unchang
address
safeti
concern
work
develop
attenu
viral
strain
delet
potenti
neurotrop
region
goal
prevent
viremia
whether
attenu
viral
strain
test
phase
studi
serv
put
challeng
strain
yet
undetermin
summari
zika
vaccin
develop
continu
multipl
candid
vaccin
clinic
trial
signific
declin
incid
evalu
vaccin
efficaci
increasingli
difficult
renew
interest
anim
model
human
infect
model
infect
author
employe
geneon
life
scienc
inc
develop
dnabas
vaccin
includ
vaccin
zika
viru
walter
reed
armi
institut
research
niaid
nation
institut
allergi
infecti
diseas
vrc
vaccin
research
center
